Cadrenal Therapeutics (CVKD) Depreciation & Amortization - Total (2022 - 2026)

Cadrenal Therapeutics has disclosed Depreciation & Amortization - Total across 5 years of filings, most recently posting $504.0 for Q2 2026.

• In Q2 2026, Depreciation & Amortization - Total rose 25.69% year-over-year to $504.0; the TTM figure through Jun 2026 stood at $1782.0 (down 4.96% YoY), while the FY2023 annual figure was $1980.0, up 56.4% from the prior year.
• Depreciation & Amortization - Total came in at $504.0 for Q2 2026 at Cadrenal Therapeutics, up from $401.0 in the prior quarter.
• In the past five years, Depreciation & Amortization - Total ranged from a high of $760.0 in Q4 2022 to a low of $190.0 in Q1 2023.
• Average Depreciation & Amortization - Total over 5 years is $511.45, with a median of $506.0 recorded in 2022.
• The largest YoY upside for Depreciation & Amortization - Total was 214.21% in 2024 against a maximum downside of 31.83% in 2024.
• Over 5 years, Depreciation & Amortization - Total stood at $760.0 in 2022, then slipped by 21.45% to $597.0 in 2023, then sank by 31.83% to $407.0 in 2024, then slipped by 1.47% to $401.0 in 2025, then rose by 25.69% to $504.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization - Total figures were $504.0 in Q2 2026, $401.0 in Q2 2025, and $407.0 in Q3 2024.